Recent Updates
Recently added Catalysts
NRXS Positive Sentiment Score: 70/100

NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Tuesday, February 27, 2024 2 min read
Key Takeaway: NeurAxis, Inc. announced its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, with a presentation scheduled for March 12, 2024. President and CEO Brian Carrico and Chief Medical Officer Dr. Adrian Miranda will represent the company at this event. NeurAxis focuses on neuromodulation therapies for chronic conditions in both children and adults, and the company is actively promoting its FDA-cleared IB-Stim™ therapy, which addresses abdominal pain linked to irritable bowel syndrome. The conference presents an opportunity for NeurAxis to engage with investors and promote its advancements in the medical technology field.

Market Sentiment Analysis

POSITIVE FACTORS

  • NeurAxis is presenting at a significant healthcare conference, indicating visibility and potential interest in their work.
  • The participation of high-level executives showcases the company's commitment to engaging with investors and stakeholders.
  • The company is advancing its proprietary therapy, IB-Stim™, which has FDA clearance, signaling regulatory confidence in its product.

Full Press Release Details

CARMEL, Ind., Feb. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that President and Chief Executive Officer Brian Carrico and Chief Medical Officer Dr. Adrian Miranda, will participate in the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12, 2024.
NeurAxis will give a corporate presentation on Tuesday, March 12, 2024, at 8:40 am ET and host investor 1x1 meetings, which can be requested through Oppenheimer. To access the live webcast, please visit the investors page of the NeurAxis website. The webcast will also be available for replay on NeurAxis’ investor relations website.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Frequently Asked Questions

What will NeurAxis present at the Oppenheimer Conference?

NeurAxis will give a corporate presentation on March 12, 2024, at 8:40 am ET.

Who will represent NeurAxis at the conference?

President Brian Carrico and CMO Dr. Adrian Miranda will represent NeurAxis.

What is IB-Stim™ therapy by NeurAxis?

IB-Stim™ is a proprietary therapy for treating functional abdominal pain in adolescents.

Who is NeurAxis, Inc. focused on helping?

NeurAxis focuses on chronic conditions affecting both children and adults.

Where can I access NeurAxis' conference webcast?

The live webcast can be accessed on NeurAxis' investor relations website.

Tags: NRXS Viatris Investor Conferences Healthcare NeurAxis IB-Stim neuromodulation healthcare conference chronic pain
Last updated: Feb 27, 2024